A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

Inclusion Criteria: * 1\. The subjects volunteered to participate in the study, signed the informed consent form, and had good compliance; * 2\. ECOG≤2 ; * 3.Life expectancy of ≥12 weeks； * 4.Age ≥18 years; * 5\. Diagnosed by histological examination and/or cytology examination, and imaging evaluation (refer to RECIST 1.1) for advanced central NSCLC; * 6\. He had not received systemic chemotherapy previously. * 7.Had at least one measurable tumor lesion according to RECIST v1.1；That is, in CT or MRI detection, the longest diameter of a single lesion is ≥10mm, or the lymph node is pathologically enlarged, and the short diameter of a single lymph node on CT scan is ≥15mm； * 8.Have adequate organ function。 Exclusion Criteria: * 1.This study was conducted five years prior to the initiation of treatment or concurrently with other malignant tumors. * 2\. Have family history of cancer. * 3.had previously undergone any form treatment, such as surgery, chemotherapy, radiation therapy, etc. * 4.Only individuals experiencing grade 1 or higher unmitigated toxic effects (excluding alopecia and fatigue) resulting from previous therapies were eligible for enrollment; neurologic toxicity needed to return to grade 1 or lower or baseline before participation. * 5.Subjects with severe and/or uncontrollable disease progression； * 6.Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; * 7.Pregnant or lactating women; * 8.Other conditions considered unsuitable for this study by the investigator.